AXSM - Axsome Therapeutics, Inc.

NasdaqGM - NasdaqGM Real Time Price. Currency in USD
3.25
+0.10 (+3.17%)
At close: 4:00PM EDT
Stock chart is not supported by your current browser
Previous Close3.15
Open3.20
Bid3.20 x 3000
Ask3.35 x 2900
Day's Range3.20 - 3.35
52 Week Range2.05 - 6.45
Volume92,399
Avg. Volume119,948
Market Cap85.322M
Beta-0.15
PE Ratio (TTM)N/A
EPS (TTM)-1.09
Earnings DateNov 6, 2018 - Nov 12, 2018
Forward Dividend & YieldN/A (N/A)
Ex-Dividend DateN/A
1y Target Est18.33
Trade prices are not sourced from all markets
  • GlobeNewswire2 days ago

    Axsome Therapeutics to Host R&D Day with Key Opinion Leaders Focused on AXS-05 and Unmet Needs in Alzheimer’s Disease Agitation

    Axsome Therapeutics, Inc. (AXSM), a clinical-stage biopharmaceutical company developing novel therapies for the management of central nervous system (CNS) disorders, today announced that it will host a research and development (R&D) day with key opinion leaders (KOLs) on Thursday, October 18, 2018 in New York City. The event will highlight AXS-05, the company’s most advanced CNS product candidate, and unmet needs in agitation associated with Alzheimer’s disease (AD). AXS-05 is in a Phase 2/3 randomized, double-blind, controlled trial (the ADVANCE-1 study) in patients with agitation associated with AD.

  • GlobeNewswire24 days ago

    Axsome Therapeutics to Present at the 20th Annual Rodman & Renshaw Global Investment Conference

    Axsome Therapeutics, Inc. (AXSM), a clinical-stage biopharmaceutical company developing novel therapies for the management of central nervous system (CNS) disorders, today announced that Herriot Tabuteau, MD, Axsome’s Chief Executive Officer, will present a corporate overview at the 20th Annual Rodman & Renshaw Global Investment Conference, sponsored by H.C. Wainwright & Co., LLC., on September 5, 2018 at 2:10 PM Eastern Time. The convention will be held at the St. Regis New York Hotel in New York, NY. A live webcast of the event can be viewed on the company’s website at www.axsome.com.

  • Associated Presslast month

    Axsome: 2Q Earnings Snapshot

    On a per-share basis, the New York-based company said it had a loss of 32 cents. The company's shares closed at $2.63. A year ago, they were trading at $5.70. _____ This story was generated by Automated ...

  • GlobeNewswirelast month

    Axsome Therapeutics Reports Second Quarter 2018 Financial Results and Provides Business Update

    Interim analysis results from two Phase 3 trials and topline results from one Phase 2 trial of AXS-05 anticipated in 4 Q 2018. Phase 3 trial of AXS-07 in acute migraine anticipated to start in 4 Q 2018. ...

  • ACCESSWIRElast month

    Axsome Therapeutics, Inc. to Host Earnings Call

    NEW YORK, NY / ACCESSWIRE / August 8, 2018 / Axsome Therapeutics, Inc. (NASDAQ: AXSM ) will be discussing their earnings results in their Q2 Earnings Call to be held on August 8, 2018 at 8:00 AM Eastern ...

  • GlobeNewswire2 months ago

    Axsome Therapeutics to Report Second Quarter 2018 Financial Results on August 8, 2018

    Axsome Therapeutics, Inc. (AXSM), a clinical-stage biopharmaceutical company developing novel therapies for the management of central nervous system (CNS) disorders, today announced that it will report its financial results for the second quarter of 2018 on Wednesday, August 8, 2018 before the opening of the U.S. financial markets. AXS-02 is currently in a Phase 3 trial in knee osteoarthritis (OA) associated with bone marrow lesions (BMLs) with an additional Phase 3 trial planned in chronic low back pain (CLBP) associated with Modic changes (MCs).

  • GlobeNewswire2 months ago

    Axsome Therapeutics Announces AXS-05 Presentation at the 2018 Alzheimer’s Association International Conference

    Axsome Therapeutics, Inc. (AXSM), a clinical-stage biopharmaceutical company developing novel therapies for the management of central nervous system (CNS) disorders, today announced a poster presentation on AXS-05 at the 2018 Alzheimer’s Association International Conference (AAIC) on July 23, 2018 in Chicago, IL. AXS-05 is a novel, oral, investigational medicine consisting of dextromethorphan and bupropion, in late-stage development for the treatment of agitation associated with Alzheimer’s disease. The presentation will highlight data correlating AXS-05 drug levels from Phase 1 trials to neurotransmitter receptor activation and to improvements in agitation symptoms in patients with Alzheimer’s disease.

  • Is Axsome Therapeutics Inc’s (NASDAQ:AXSM) CEO Incentives Align With Yours?
    Simply Wall St.4 months ago

    Is Axsome Therapeutics Inc’s (NASDAQ:AXSM) CEO Incentives Align With Yours?

    Leading Axsome Therapeutics Inc (NASDAQ:AXSM) as the CEO, Herriot Tabuteau took the company to a valuation of US$83.04M. Recognizing whether CEO incentives are aligned with shareholders is a crucial partRead More...

  • Associated Press4 months ago

    Axsome: 1Q Earnings Snapshot

    On a per-share basis, the New York-based company said it had a loss of 19 cents. The company's shares closed at $3.35. A year ago, they were trading at $3.90. _____ This story was generated by Automated ...

  • ACCESSWIRE4 months ago

    Axsome Therapeutics, Inc. to Host Earnings Call

    NEW YORK, NY / ACCESSWIRE / May 8, 2018 / Axsome Therapeutics, Inc. (NASDAQ: AXSM ) will be discussing their earnings results in their Q1 Earnings Call to be held on May 8, 2018 at 8:00 AM Eastern Time. ...

  • ACCESSWIRE5 months ago

    Wired News – Axsome Therapeutics Initiated Phase-2 Clinical Trial of AXS-05 in Smoking Cessation

    LONDON, UK / ACCESSWIRE / April 25, 2018 / Active-Investors.com has just released a free research report on Axsome Therapeutics, Inc. (NASDAQ: AXSM). If you want access to this report all you need to do is sign up now by clicking the following link www.active-investors.com/registration-sg/?symbol=AXSM as the Company's latest news hit the wire. On April 23, 2018, the Company announced that it has enrolled first patient into a Phase-2 trial assessing AXS-05 for smoking cessation treatment.

  • Should You Be Concerned About Axsome Therapeutics Inc’s (NASDAQ:AXSM) Investors?
    Simply Wall St.5 months ago

    Should You Be Concerned About Axsome Therapeutics Inc’s (NASDAQ:AXSM) Investors?

    In this analysis, my focus will be on developing a perspective on Axsome Therapeutics Inc’s (NASDAQ:AXSM) latest ownership structure, a less discussed, but important factor. The impact of a company’sRead More...